Format

Send to

Choose Destination
J Am Acad Dermatol. 2019 Sep;81(3):702-708. doi: 10.1016/j.jaad.2019.05.022. Epub 2019 May 13.

Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa.

Author information

1
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
2
Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: Christopher_Sayed@med.unc.edu.

Abstract

BACKGROUND:

Few data exist to guide infliximab dosing in hidradenitis suppurativa (HS).

OBJECTIVES:

To determine optimal infliximab dosing for patients with HS based on treatment response and achievement of stable dosing.

METHODS:

Retrospective cohort study of 52 patients with HS treated with infliximab. Primary outcome was achievement of stable dosing regimen for at least 8 weeks. Secondary outcomes were time to discontinuation, time to titration, changes to inflammatory markers, and clinical response.

RESULTS:

Thirty-five patients (67%) achieved stable dosing, most at a schedule of 10 mg/kg every 6 or 8 weeks. At 1 year from initiation, most patients (64%) required dose escalation. Patients tolerated infliximab well and achieved significant improvements in abscess and nodule count, draining sinuses, and erythrocyte sedimentation rate.

LIMITATIONS:

Retrospective nature and lack of HS clinical response data for many patients.

CONCLUSIONS:

Infliximab 10 mg/kg every 6 or 8 weeks may be a reasonable starting dosage for most patients.

KEYWORDS:

clinical research; drug response; general dermatology; hidradenitis; infliximab; medical dermatology

PMID:
31095972
DOI:
10.1016/j.jaad.2019.05.022

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center